Harrow, Inc. (HROW): Depreciation & Amortization
$1.92M
Year ended 2025-12-31
$1.87M
Trailing 12 months to 2026-06-30
+9.0%
3-year compound annual growth
+0.4%
5-year compound annual growth
+22.3%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.92M | +3.5% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $1.85M | +20.9% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $1.53M | +3.6% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $1.48M | -14.0% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $1.72M | -8.7% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $1.88M | -2.9% | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | $1.94M | +20.4% | 2021-03-08, From 2019-01-01 |
| 2018-12-31 | $1.61M | +14.8% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $1.40M | +32.8% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $1.05M | +313.7% | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | $255.0K | +589.2% | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | $37.0K | n/a | 2016-03-23, From 2014-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Harrow, Inc. (HROW) | 2025-12-31 | $1.92M | +3.5% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $16.11M | +535.0% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $33.77M | -4.2% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $3.00M | -34.8% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $6.02M | -2.2% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $1.31M | +7.0% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $1.10M | -8.3% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $7.51M | +41.7% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $10.00M | 0.0% |
Compare HROW, VREOF, LGND, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗